losartan and Aortic Aneurysm studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Aortic Aneurysm: An abnormal balloon- or sac-like dilatation in the wall of AORTA.

Research Excerpts

Excerpt	Relevance	Reference
"Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups."	9.27	Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018)
" atenolol in aortic dilation progression in Marfan syndrome (MFS) patients."	9.22	Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. ( Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G, 2016)
"We conducted a randomized, double-blind trial of losartan (100 mg QD) versus atenolol (50 mg QD) for 6 months in adults with Marfan syndrome."	9.20	Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. ( Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP, 2015)
"Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown."	7.77	Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011)
"Treatment with losartan will be compared with no additional treatment after 3 years of follow-up."	6.75	Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. ( Baars, MJ; de Witte, P; Groenink, M; Mulder, BJ; Radonic, T; Zwinderman, AH, 2010)
"Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease."	5.36	Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010)
"Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups."	5.27	Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018)
" atenolol in aortic dilation progression in Marfan syndrome (MFS) patients."	5.22	Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. ( Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G, 2016)
"We conducted a randomized, double-blind trial of losartan (100 mg QD) versus atenolol (50 mg QD) for 6 months in adults with Marfan syndrome."	5.20	Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. ( Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP, 2015)
"Recent studies have demonstrated that blockade of the angiotensin II type 1 receptor with losartan decreases aortic damage in an animal model of Marfan syndrome (a KI mouse model with a pathogenic mutation in the gene coding for fibrillin-1)."	5.14	Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. ( Aegerter, P; Arnoult, F; Boileau, C; Bouffard, C; Collignon, P; Delrue, MA; Detaint, D; Dulac, Y; Faivre, LO; Gautier, M; Hoffman, I; Jondeau, G; Odent, S; Plauchu, H; Tchitchinadze, M; Tubach, F, 2010)
" In addition, recent studies show that angiotensin II type 1 receptor (AT1R) signaling enhances cardiovascular pathologies in MFS, and the angiotensin II receptor blocker losartan has the potential to inhibit aortic aneurysm formation."	4.93	Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes. ( Akazawa, H; Fujita, D; Fujiwara, T; Hara, H; Harada, M; Inuzuka, R; Komuro, I; Nawata, K; Takeda, N; Taniguchi, Y; Toko, H; Yagi, H, 2016)
"This study confirms that angiotensin II type 1 receptor antagonism (losartan) decreases aortic aneurysm growth in a mouse model of MFS."	3.88	The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome. ( Clijsters, M; Herijgers, P; Meuris, B; Schepens, J; Verbrugghe, P; Verhoeven, J; Vervoort, D, 2018)
"Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown."	3.77	Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011)
"Treatment with losartan will be compared with no additional treatment after 3 years of follow-up."	2.75	Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. ( Baars, MJ; de Witte, P; Groenink, M; Mulder, BJ; Radonic, T; Zwinderman, AH, 2010)
"Aortic aneurysms are life-threatening and often associated with defects in connective tissues and mutations in smooth muscle cell (SMC) contractile proteins."	1.39	Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. ( Huang, J; Ikeda, Y; Inagami, T; Le, VP; Lin, Y; Papke, CL; Patel, M; Wagenseil, JE; Yamashiro, Y; Yanagisawa, H, 2013)
"Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease."	1.36	Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010)
"Losartan is an emerging therapy that may help slow down the rate of arterial dilatation."	1.35	Loeys-Dietz syndrome: a Marfan-like syndrome associated with aggressive vasculopathy. ( Choo, JT; Lai, AH; Tan, TH; Wong, KY, 2009)

Research

Studies (32)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (15.63)	29.6817
2010's	25 (78.13)	24.3611
2020's	2 (6.25)	2.80

Authors	Studies
Sun, Y	1
Asano, K	1
Sedes, L	1
Cantalupo, A	1
Hansen, J	1
Iyengar, R	1
Walsh, MJ	1
Ramirez, F	3
Verbrugghe, P	1
Verhoeven, J	1
Clijsters, M	1
Vervoort, D	1
Schepens, J	1
Meuris, B	1
Herijgers, P	1
Teixido-Tura, G	2
Forteza, A	2
Rodríguez-Palomares, J	2
González Mirelis, J	1
Gutiérrez, L	2
Sánchez, V	2
Ibáñez, B	1
García-Dorado, D	2
Evangelista, A	2
Zhou, Z	1
Peters, AM	1
Wang, S	1
Janda, A	1
Chen, J	1
Zhou, P	1
Arthur, E	1
Kwartler, CS	1
Milewicz, DM	1
Li, L	1
Yamani, N	1
Al-Naimat, S	1
Khurshid, A	1
Usman, MS	1
Huang, J	1
Yamashiro, Y	1
Papke, CL	1
Ikeda, Y	1
Lin, Y	1
Patel, M	1
Inagami, T	1
Le, VP	1
Wagenseil, JE	1
Yanagisawa, H	1
Gallo, EM	1
Loch, DC	1
Habashi, JP	4
Calderon, JF	1
Chen, Y	3
Bedja, D	4
van Erp, C	2
Gerber, EE	1
Parker, SJ	1
Sauls, K	1
Judge, DP	4
Cooke, SK	1
Lindsay, ME	2
Rouf, R	1
Myers, L	2
ap Rhys, CM	1
Kent, KC	1
Norris, RA	1
Huso, DL	2
Dietz, HC	7
Bowen, JM	1
Connolly, HM	1
Lacro, RV	2
Sleeper, LA	1
Yetman, AT	1
Bradley, TJ	1
Colan, SD	1
Pearson, GD	1
Selamet Tierney, ES	1
Levine, JC	1
Atz, AM	1
Benson, DW	1
Braverman, AC	1
Chen, S	1
De Backer, J	1
Gelb, BD	1
Grossfeld, PD	1
Klein, GL	1
Lai, WW	1
Liou, A	1
Loeys, BL	3
Markham, LW	1
Olson, AK	1
Paridon, SM	1
Pemberton, VL	1
Pierpont, ME	1
Pyeritz, RE	1
Radojewski, E	1
Roman, MJ	1
Sharkey, AM	1
Stylianou, MP	1
Wechsler, SB	1
Young, LT	1
Mahony, L	2
Treasure, T	1
Pepper, J	1
Mohiaddin, R	1
Ziganshin, BA	1
Mukherjee, SK	1
Elefteriades, JA	2
Mallat, Z	1
Tedgui, A	1
Bhatt, AB	1
Buck, JS	1
Zuflacht, JP	1
Milian, J	1
Kadivar, S	1
Gauvreau, K	1
Singh, MN	1
Creager, MA	1
Lengellé, C	1
Bejan-Angoulvant, T	1
Beau-Salinas, F	1
Jonville-Béra, AP	1
Sanz, P	1
Gracia, T	1
Centeno, J	1
Rufilanchas, JJ	1
Cortina, J	1
Ferreira-González, I	1
O'Rourke, MF	1
Adji, A	1
Weber, T	1
Takeda, N	1
Yagi, H	1
Hara, H	1
Fujiwara, T	1
Fujita, D	1
Nawata, K	1
Inuzuka, R	1
Taniguchi, Y	1
Harada, M	1
Toko, H	1
Akazawa, H	1
Komuro, I	1
Gambarin, FI	1
Favalli, V	1
Serio, A	1
Regazzi, M	1
Pasotti, M	1
Klersy, C	1
Dore, R	1
Mannarino, S	1
Viganò, M	1
Odero, A	1
Amato, S	1
Tavazzi, L	1
Arbustini, E	1
Choo, JT	1
Tan, TH	1
Lai, AH	1
Wong, KY	1
Radonic, T	1
de Witte, P	1
Baars, MJ	1
Zwinderman, AH	1
Mulder, BJ	1
Groenink, M	1
Collins, MJ	1
Detaint, D	1
Aegerter, P	1
Tubach, F	1
Hoffman, I	1
Plauchu, H	1
Dulac, Y	1
Faivre, LO	1
Delrue, MA	1
Collignon, P	1
Odent, S	1
Tchitchinadze, M	1
Bouffard, C	1
Arnoult, F	1
Gautier, M	1
Boileau, C	1
Jondeau, G	1
Nistala, H	1
Lee-Arteaga, S	1
Carta, L	2
Cook, JR	1
Smaldone, S	1
Siciliano, G	1
Rifkin, AN	1
Rifkin, DB	2
Couzin-Frankel, J	1
Holm, TM	3
Doyle, JJ	2
Kim, D	1
Schoenhoff, F	2
Cohn, RD	2
Thomas, CJ	1
Patnaik, S	1
Marugan, JJ	1
Aziz, H	1
Modiri, AN	1
Moltzer, E	1
te Riet, L	1
Swagemakers, SM	1
van Heijningen, PM	1
Vermeij, M	1
van Veghel, R	1
Bouhuizen, AM	1
van Esch, JH	1
Lankhorst, S	1
Ramnath, NW	1
de Waard, MC	1
Duncker, DJ	1
van der Spek, PJ	1
Rouwet, EV	1
Danser, AH	1
Essers, J	1
Merk, DR	1
Chin, JT	1
Dake, BA	1
Maegdefessel, L	1
Miller, MO	1
Kimura, N	1
Tsao, PS	1
Iosef, C	1
Berry, GJ	1
Mohr, FW	1
Spin, JM	1
Alvira, CM	1
Robbins, RC	1
Fischbein, MP	1
Travis, J	1
Cooper, TK	1
Klein, EC	1
Liu, G	1
Calvi, C	1
Podowski, M	1
Neptune, ER	1
Halushka, MK	1
Gabrielson, K	1
Naina, HV	1
Harris, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)[NCT00429364]	Phase 3	608 participants (Actual)	Interventional	2007-01-31	Completed
Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124]	Phase 3	291 participants (Anticipated)	Interventional	2008-07-31	Recruiting
Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893]	Phase 3	303 participants (Actual)	Interventional	2008-09-30	Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score

Intervention	cm/year (Least Squares Mean)
Atenolol	0.069
Losartan	0.075

The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area

Annual Rate of Change in Arm Span to Height Ratio

Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.

Annual Rate of Change in Body Mass Index

Annual Rate of Change in Body Mass Index for Age Z-score

Annual Rate of Change in Height

Annual Rate of Change in Height-for-age Z-score

Annual Rate of Change in the Absolute Diameter of the Aortic Annulus

Annual Rate of Change in the Absolute Diameter of the Ascending Aorta

Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area

Annual Rate of Change in Upper to Lower Segment Ratio

Annual Rate of Change in Weight

Annual Rate of Change in Weight-for-age Z-score

Annual Rate of Change in Weight-for-height Z-score

Event Rate of Aortic Dissection.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.139
Losartan	-0.107

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.279
Losartan	-0.175

Intervention	1/year (Least Squares Mean)
Atenolol	0.001
Losartan	0.001

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.140
Losartan	-0.114

Intervention	kg/m^2 per year (Least Squares Mean)
Atenolol	0.063
Losartan	0.076

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.007
Losartan	0.021

Intervention	cm/year (Least Squares Mean)
Atenolol	0.822
Losartan	0.935

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.046
Losartan	0.019

Intervention	cm/year (Least Squares Mean)
Atenolol	0.015
Losartan	0.030

Intervention	cm/year (Least Squares Mean)
Atenolol	0.039
Losartan	0.044

Intervention	(mm^2/m^2)/year (Least Squares Mean)
Atenolol	0.005
Losartan	0.001

Intervention	1/year (Least Squares Mean)
Atenolol	-0.014
Losartan	-0.015

Intervention	kg/year (Least Squares Mean)
Atenolol	0.239
Losartan	0.229

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.011
Losartan	0.019

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.001
Losartan	-0.157

Percentage of participants who had aortic dissection over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of Aortic-Root Surgery

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.7

Percentage of participants who had aortic-root surgery over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of Death

Intervention	Percentage of participants (Number)
Atenolol	3.4
Losartan	6.0

Percentage of participants who died over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.3

Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	112	10	84	0	54	7	21	2	60	2	52	2	60	0	25	0	5	5	60	0	54	1	43	3	15	2	106	0	47	1	10	0	47	0	30	1	23	0	35	1	44	0	35	0	59	2	60	3	13	0	2	0	21	3
Losartan	114	10	105	0	49	3	23	1	61	2	53	3	58	2	27	1	9	9	53	0	58	5	38	0	14	1	117	2	59	0	3	0	61	1	35	0	23	0	43	1	35	0	34	1	58	4	67	2	15	0	3	0	16	1

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	202	27	152	7	89	13	51	5	108	6	100	7	119	6	60	2	21	21	86	0	114	14	75	1	36	2	188	3	117	1	29	0	119	2	99	0	81	1	94	1	77	1	73	0	148	6	137	5	22	0	6	0	105	10
Losartan	208	20	153	5	86	13	46	8	107	4	94	4	105	0	61	0	16	16	101	0	106	1	72	3	32	5	186	3	113	1	16	0	121	8	78	0	75	2	90	3	66	0	66	0	124	7	134	8	27	1	5	0	108	12

Article	Year
Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. European journal of preventive cardiology, 2020, Volume: 27, Issue:13 Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Humans; Losartan; Marfan Syndrome	2020
Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes. International heart journal, 2016, May-25, Volume: 57, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Disease Management; Fibrillin-1;	2016
Is losartan the true panacea for aneurysm disease? PRO. Cardiology clinics, 2010, Volume: 28, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Humans; Losartan; Renin-Angiotens	2010

Article	Year
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. Journal of the American College of Cardiology, 2018, 10-02, Volume: 72, Issue:14 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aorti	2018
Atenolol versus losartan in children and young adults with Marfan's syndrome. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm;	2014
Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular medicine (London, England), 2015, Volume: 20, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneur	2015
Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European heart journal, 2016, Mar-21, Volume: 37, Issue:12 Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Child;	2016
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. Journal of cardiovascular medicine (Hagerstown, Md.), 2009, Volume: 10, Issue:4 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneu	2009
Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials, 2010, Jan-12, Volume: 11 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Aortic Dissection; Biopsy; Echocard	2010
Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Archives of cardiovascular diseases, 2010, Volume: 103, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Disease Models, Animal; Double-Bl	2010

Article	Year
Dissecting aortic aneurysm in Marfan syndrome is associated with losartan-sensitive transcriptomic modulation of aortic cells. JCI insight, 2023, 05-22, Volume: 8, Issue:10 Topics: Animals; Aorta; Aortic Aneurysm; Aortic Aneurysm, Thoracic; Aortic Dissection; Humans; Losartan; Mar	2023
The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome. Journal of cardiovascular pharmacology, 2018, Volume: 71, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Dilatation, Pathologic; Di	2018
Reversal of Aortic Enlargement Induced by Increased Biomechanical Forces Requires AT1R Inhibition in Conjunction With AT2R Activation. Arteriosclerosis, thrombosis, and vascular biology, 2019, Volume: 39, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Ao	2019
Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Science translational medicine, 2013, May-01, Volume: 5, Issue:183 Topics: Angiotensin II; Animals; Aorta; Aortic Aneurysm; Biomarkers; Biomechanical Phenomena; Blood Pressure	2013
Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. The Journal of clinical investigation, 2014, Volume: 124, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Cells, Cul	2014
Of Marfan's syndrome, mice, and medications. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2014
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
[Drugs news]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2015, Volume: 22, Issue:11 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Anticonvu	2015
Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al. Vascular medicine (London, England), 2016, Volume: 21, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; At	2016
Loeys-Dietz syndrome: a Marfan-like syndrome associated with aggressive vasculopathy. Singapore medical journal, 2009, Volume: 50, Issue:10 Topics: Anti-Arrhythmia Agents; Aortic Aneurysm; Echocardiography; Female; Humans; Infant, Newborn; Loeys-Di	2009
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Human molecular genetics, 2010, Dec-15, Volume: 19, Issue:24 Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins;	2010
Medicine. Frightening risk of Marfan syndrome, and potential treatment, elucidated. Science (New York, N.Y.), 2011, Apr-15, Volume: 332, Issue:6027 Topics: Animals; Aortic Aneurysm; Clinical Trials as Topic; Extracellular Signal-Regulated MAP Kinases; Huma	2011
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (New York, N.Y.), 2011, Apr-15, Volume: 332, Issue:6027 Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progres	2011
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science (New York, N.Y.), 2011, Apr-15, Volume: 332, Issue:6027 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2011
Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade. PloS one, 2011, Volume: 6, Issue:8 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aorta, Thoracic;	2011
miR-29b participates in early aneurysm development in Marfan syndrome. Circulation research, 2012, Jan-20, Volume: 110, Issue:2 Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Apoptosis; Ap	2012
Medicine. Old drug, new hope for Marfan syndrome. Science (New York, N.Y.), 2006, Apr-07, Volume: 312, Issue:5770 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Clin	2006
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (New York, N.Y.), 2006, Apr-07, Volume: 312, Issue:5770 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta; Ao	2006
ACE inhibitors and aortic rupture. Lancet (London, England), 2006, Nov-04, Volume: 368, Issue:9547 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2006

losartan and Aortic Aneurysm